vatalanib has been researched along with GDC-0879 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (GDC-0879) | Trials (GDC-0879) | Recent Studies (post-2010) (GDC-0879) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 10 | 0 | 9 |
| Protein | Taxonomy | vatalanib (IC50) | GDC-0879 (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.2003 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 0.063 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.063 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
1 other study(ies) available for vatalanib and GDC-0879
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |